XML 23 R73.htm IDEA: XBRL DOCUMENT v2.4.1.9
Discontinued Operations Discontinued Operations (Details) (USD $)
0 Months Ended 3 Months Ended
Sep. 01, 2014
Mar. 31, 2015
Mar. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Loss from discontinued operations (net of tax)   $ 0us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax $ (1,769,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax
Antioxidant, Ibuprofen and Propofol Assets      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Cash proceeds from divestitures, net 104,700,000us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
   
Working capital settlement   7,600,000us-gaap_ProceedsFromDivestitureOfBusinesses
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
 
Net sales   0us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
56,836,000us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
Loss from discontinued operations   0us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
(2,513,000)us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
Income tax benefit   0us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
(744,000)us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
Loss from discontinued operations (net of tax)   $ 0us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember
$ (1,769,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= alb_AntioxidantIbuprofenandPropofolAssetsMember